EMA Lapsed: Kogenate Bayer (octocog alfa) — Bayer AG

View source ↗

Summary

EMA indicates that Kogenate Bayer (octocog alfa) has lapsed (withdrawn) from regulatory status in the European market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• KOGENATE Bayer (antihemophilic factor (recombinant))

Snippet

Status: Lapsed. Therapeutic area: Hemophilia A. MAH: Bayer AG. Decision date: 16/11/2017